91252-54-9

Usage

Uses

Used in Pharmaceutical Industry:
ETHYL 5-TERT-BUTYLISOXAZOLE-3-CARBOXYLATE is used as a building block or intermediate for the synthesis of pharmaceuticals, contributing to the development of potential drug candidates and bioactive compounds.
Used in Agrochemical Industry:
ETHYL 5-TERT-BUTYLISOXAZOLE-3-CARBOXYLATE is used as a building block or intermediate for the synthesis of agrochemicals, aiding in the creation of effective and innovative products for agricultural applications.
Used in Research and Development:
ETHYL 5-TERT-BUTYLISOXAZOLE-3-CARBOXYLATE is used as a starting material in research and development applications within the chemical and pharmaceutical industries, enabling the creation of new molecules with diverse biological activities.

InChI:InChI=1/C10H15NO3/c1-5-13-9(12)7-6-8(14-11-7)10(2,3)4/h6H,5H2,1-4H3

Upstream product

• 94122-76-6 ethyl 2-hydroxy-5,5-dimethyl-4-oxohex-2-enoate 
• 75-97-8 3,3-dimethyl-butan-2-one 
• 95-92-1 oxalic acid diethyl ester 
• 94122-76-6 (Z)-ethyl 2-hydroxy-5,5-dimethyl-4-oxohex-2-enoate 
• 917-92-0 3,3-Dimethylbut-1-yne 
• 861135-87-7 chlorohydroxyimino-acetic acid ethyl ester 
• 13395-36-3 ethyl trimethylacetopyruvate 

Downstream Products

• 130402-98-1 5-tert-Butyl-isoxazole-3-carboxylic acid (2,6-dimethyl-phenyl)-amide 
• 202817-06-9 5-tert-butyl-3-(hydroxymethyl)isoxazole 
• 1196103-88-4 2-bromo-1-(5-tert-butylisoxazol-3-yl)ethanone 
• 1423915-05-2 3-(5-tert-butyl-isoxazol-3-yl)-2-[(2-chlorophenyl)-hydrazono]-3-oxo-propionitrile 
• 263707-17-1 3-(5-tert-butyl-isoxazol-3-yl)-2-[(4-chlorophenyl)-hydrazono]-3-oxo-propionitrile 
• 1423915-08-5 3-(5-tert-butyl-isoxazol-3-yl)-2-[(2,5-dichlorophenyl)-hydrazono]-3-oxo-propionitrile 
• 263707-14-8 3-(5-tert-butyl-isoxazol-3-yl)-3-oxo-2-(phenyl-hydrazono)-propionitrile 
• 263707-16-0 α-(2-(3-chlorophenyl)hydrazinylidene)-5-(1,1-dimethylethyl)-β-oxo-3-isoxazolepropanenitrile 

Relevant academic research and scientific papers

BTK INHIBITORS

Provided are compounds of Formula (I): or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R7, R8, R9, A1, A2, Q1, Q2, Q3, A, Z, m and n are as defined herein; pharmaceutical compositions comprising said compounds or pharmaceutically acceptable salts thereof, and pharmaceutically acceptable excipients; and methods of treating a disorder responsive to inhibition of Bruton's tyrosine kinase using said compounds, or pharmaceutically acceptable salts thereof, or said pharmaceutical compositions.

METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION

Mutations in oncogenes and tumor suppressors contribute to the development and progression of cancer. The present disclosure describes compounds and methods to recover wild-type function to p53 mutants. The compounds of the present disclosure can bind to mutant p53 and restore the ability of the p53 mutant to bind DNA and activate downstream effectors involved in tumor suppression. The disclosed compounds can be used to reduce the progression of cancers that contain a p53 mutation.

Development of a continuous flow photoisomerization reaction converting isoxazoles into diverse oxazole products

A continuous flow process is presented, which directly converts isoxazoles into their oxazole counterparts via a photochemical transposition reaction. This results in the first reported exploitation of this transformation to establish its scope and synthe

Structure-Activity Relationship Studies of Substituted 2-(Isoxazol-3-yl)-2-oxo-N′-phenyl-acetohydrazonoyl Cyanide Analogues: Identification of Potent Exchange Proteins Directly Activated by cAMP (EPAC) Antagonists

Exchange proteins directly activated by cAMP (EPAC) as guanine nucleotide exchange factors mediate the effects of the pivotal second messenger cAMP, thereby regulating a wide variety of intracellular physiological and pathophysiological processes. A series of novel 2-(isoxazol-3-yl)-2-oxo-N′-phenyl-acetohydrazonoyl cyanide EPAC antagonists was synthesized and evaluated in an effort to optimize properties of the previously identified high-throughput (HTS) hit 1 (ESI-09). Structure-activity relationship (SAR) analysis led to the discovery of several more active EPAC antagonists (e.g., 22 (HJC0726), 35 (NY0123), and 47 (NY0173)) with low micromolar inhibitory activity. These inhibitors may serve as valuable pharmacological probes to facilitate our efforts in elucidating the biological functions of EPAC and developing potential novel therapeutics against human diseases. Our SAR results have also revealed that further modification at the 3-, 4-, and 5-positions of the phenyl ring as well as the 5-position of the isoxazole moiety may allow for the development of more potent EPAC antagonists.

Efficient synthesis of ESI-09, a novel non-cyclic nucleotide EPAC antagonist

A concise and efficient synthetic approach to producing a novel non-cyclic nucleotide EPAC antagonist ESI-09 and its new analogs is reported. Key features of the synthesis include a mild and reliable one-pot procedure for an isoxazole synthon, as well as a modified one-pot protocol for the cyanomethyl ketone key intermediate. The synthesis requires inexpensive starting materials and only three linear steps for the completion in a total yield of 53%.

Sulfone compounds which modulate the CB2 receptor

Compounds which modulate the CB2 receptor are disclosed. Compounds according to the invention bind to and are agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are additionally useful for treating p

SULFONE COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR

Compounds which modulate the CB2 receptor are disclosed. Compounds according to the invention bind to and are agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are additionally useful for treating p

Analogs of 4-hydroxyisoleucine and uses thereof

The invention relates to analogs of 4-hydroxyisoleucine, and to lactones, pharmaceutically acceptable salts, and prodrugs thereof, to processes for their preparation, and to pharmaceutical compositions comprising the same. The analogs of the invention stimulate both glucose uptake and insulin secretion, and may thus be useful for the prevention and treatment of disorders of carbohydrate or lipid metabolism, including diabetes mellitus (type 1 and type 2 diabetes), pre-diabetes, and Metabolic Syndrome.

Compounds and compositions for use in the prevention and treatment of obesity and related syndromes

The invention relates to 4-hydroxyisoleucine, isomers, analogs, lactones, salts, and prodrugs thereof, to processes for their preparation, and to pharmaceutical compositions comprising the same. More particularly, the invention relates to the use of those compounds in the prevention and treatment of obesity and related syndromes.

MALONONITRILE COMPOUND AS PESTICIDES

The present invention provides a malononitrile compound represented by the formula (I): wherein any one of X1, X2, X3 and X4 is CR100, wherein R100 is a group represented by the formula: the other three of X1, X2, X3 and X4 each represent nitrogen or CR5, provided that 1 to 3 of X1, X2, X3 and X4 represent nitrogen, and Z represents oxygen, sulfur or NR6, which has pest-controlling activity.